|
Effect of Add on Antidiabetic Drugs on Cognitive Scores in Type 2 Diabetes Mellitus Patients with Mild Cognitive Impairment
|
|
| Author:
|
SREEJITH K, MALARKODI VELRAJ
|
| Abstract:
|
Background & objectives: Type 2 diabetes mellitus increase the risk of developing cognitive decline. Antidiabetic drugs play multiple roles in prevention as well as aggravation of cognitive decline. This study aimed to
assess the add on effect of commonly using anti-diabetic medicines on cognitive status among diabetic patients
with mild cognitive impairment (MCI).
Methods: A cross sectional study was conducted in a tertiary care teaching hospital. Montreal Cognitive
Assessment (MoCA) and Addenbrooke’s Cognitive Examination III (ACE-III) were used to access the cognitive
status on patients. Statistical analysis was performed by using SPSS version 21.0. Independent sample KruskalWallis test was used to analyze the outcome.
Results: A total of 465 diabetes patients on treatment with metformin and/ or insulin and/ or glimipride were
included in this study. The prevalence of MCI was found to 24.64%. The mean MoCA score for the patients
with MCI was found to be 20.06 (SD: 1.10) and ACE-III score is 77.71 (SD: 1.89). MoCA scores were
significantly different for add on antidiabetes drugs studied, H(2) =8.241, p=0.016. Significant difference was
found when metformin as add on drug compared to Insulin as add on drug (p=0,024, r=-0.149). However no
significant differences was found between MOCA score when metformin as add on drug compared to no
second drug (p=0.225, r=0.089) and Insulin compared to no second drug (p=0.681, r= -0.083).
Conclusion: Metformin helps significantly to improve cognitive impairment in type 2 diabetes mellitus patients
as add on drug than insulin as add on drug.
|
| Keyword:
|
ACE-III, Cognitive impairment, Glimipride, Insulin, Metformin, MoCA
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.02.097
|
| Download:
|
Request For Article
|
|
|